Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Opdivo (nivolumab) - Ono Pharma, BMS

bendamustine - Generic mfg.

TT11 - Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute

fludarabine IV - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

Adcetris (brentuximab vedotin) - Seagen, Takeda

https://ashpublications.org/blood/article/140/Supplement1/12728/490314/Phase-1b-2-Study-of-Autologous-CD30-CAR-T-Cells-in

Matthew Mei; Sairah Ahmed; Amer Beitinjaneh; Natalie S. Grover; Carlos A. Ramos; Khong Bee Kang; Paul I. Nadler; Aung Myo; Ivan D. Horak; Helen E. Heslop

Nov 29, 2022